Patents by Inventor Mitesh Borad

Mitesh Borad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted therapies for cancer
    Patent number: 11866789
    Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: January 9, 2024
    Assignee: The Translational Genomics Research Institute
    Inventors: Sara Byron, Jessica Aldrich, John Carpten, David Craig, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
  • TARGETED THERAPIES FOR CANCER
    Publication number: 20220042112
    Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.
    Type: Application
    Filed: August 25, 2021
    Publication date: February 10, 2022
    Applicants: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Sara Byron, Jessica Aldrich, John Carpten, David Craig, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
  • Targeted therapies for cancer
    Patent number: 11186875
    Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: November 30, 2021
    Assignees: The Translational Genomics Research Institute, Mayo Foundation for Medical Education and Research
    Inventors: John Carpten, David Craig, Sara Byron, Jessica Aldrich, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
  • TARGETED THERAPIES FOR CANCER
    Publication number: 20180171412
    Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.
    Type: Application
    Filed: June 13, 2016
    Publication date: June 21, 2018
    Inventors: John Carpten, David Craig, Sara Byron, Jessica Aldrich, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart